Back to Stakeholders

Funding & InvestmentGovernment FundingGrants, Subsidies & Contracts

Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchSpecialized Academic Departments and Institutes

Funding & InvestmentGovernment Funding

Funding & Investment

Research, Drug Development & ManufacturingAcademic & Non-Profit Research

Research, Drug Development & Manufacturing

Government, Policy & Advocacy

Government, Policy & AdvocacyPublic Sector Health & Drug Governance

Government, Policy & AdvocacyPublic Sector Health & Drug GovernanceNational Ministries & Federal Agencies

National Institute of Mental Health (NIMH)

Also known as: NIMH

30 Trials

U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.

Academic Research

0 papers

Published Papers

0

Trial Involvement

30

Distinct Focus Topics

0

Latest Publication

Unknown

Quick Facts

Type: government
Website: Visit

Sponsored Trials

10

RecruitingII, III

Understanding and Treating Suicidal Ideation With Ketamine

Start Date: April 8, 2025
Compounds: Ketamine

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

Start Date: August 14, 2024
Compounds: Placebo

Behavioural Activation Therapy and Esketamine for Resistant Depression

Start Date: June 1, 2024
Compounds: Esketamine

[11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine

Start Date: February 8, 2023

Long-term Observation of Participants With Mood Disorders

Start Date: June 17, 2021

Unknown statusII

Psilocybin Versus Ketamine in Treatment-Resistant Depression (PSIKET_001)

Start Date: May 1, 2021
Compounds: Psilocybin, Ketamine, Placebo

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

Start Date: January 11, 2021
Compounds: Ketamine, Placebo

Mechanism of Action Underlying Ketamine’s Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

Start Date: January 21, 2020
Compounds: Ketamine, Placebo

Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

Start Date: May 25, 2017
Compounds: Ketamine, Placebo

Rapid Antidepressant Effects of Ketamine in Major Depression

Start Date: July 26, 2004
Compounds: Ketamine, Placebo

Collaborated Trials

20

Psilocybin Therapy for Psychological Distress in Palliative Patients (PsyPal)

Start Date: March 1, 2025
Compounds: Psilocybin

Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery (PREPARE-2)

Start Date: February 7, 2025
Compounds: Ketamine

Enrolling by invitationNA

Cognitive Training as an Adjunct to Ketamine in Real-world Clinics

Start Date: November 1, 2024

Examining Mu Opioid Mechanisms of Ketamine’s Rapid Effects in OCD (MKET2) (MKET2)

Start Date: February 24, 2024
Compounds: Ketamine, Placebo

Neural Circuit Effects of Ketamine in Depression

Start Date: January 31, 2024
Compounds: Ketamine, Placebo

Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

Start Date: January 1, 2024
Compounds: Ketamine, Placebo

Enhancing Week-long Psychological Treatment for PTSD With Ketamine

Start Date: August 21, 2023
Compounds: Ketamine, Placebo

Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine

Start Date: November 8, 2022
Compounds: Ketamine, Placebo

Ketamine Treatment of Youth Suicide Attempters

Start Date: June 27, 2022
Compounds: Ketamine, Placebo

Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

Start Date: January 21, 2022
Compounds: Ketamine, Placebo

Ketamine in the Treatment of Suicidal Depression

Start Date: June 1, 2021
Compounds: Ketamine, Placebo

Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention (ENDURE)

Start Date: March 5, 2021

Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents

Start Date: January 5, 2021
Compounds: Ketamine

Temporarily not availableIV

IM Ketamine vs Midazolam for Suicidal ER Patients

Start Date: January 2, 2021
Compounds: Ketamine, Placebo

Temporarily not availableI, II

Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)

Start Date: January 1, 2021
Compounds: Ketamine

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study

Start Date: November 13, 2018
Compounds: Psilocybin, Placebo

Physiological and Cognitive Biomarkers for Ketamine’s Antidepressant Effects

Start Date: July 1, 2016
Compounds: Ketamine

miRNAs, Suicide, and Ketamine – Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome

Start Date: April 20, 2015
Compounds: Ketamine

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

Start Date: December 1, 2014
Compounds: Ketamine, Placebo

Biomarkers of Fast Acting Therapies in Major Depression

Start Date: June 1, 2014
Compounds: Ketamine